Figure 3: Cisplatin-packaging MPs inhibit ovarian cancer growth in SCID mice.
From: Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
(a,b) A2780 cells were i.p. injected to SCID mice (n=12 per group). From the next day, mouse was administered with MPs or with single cisplatin (2 μg g−1) or PBS by i.p. injection once per day for continuous 5 days. After 14 days, an additional treatment was administered once per day for 5 days. After 30 days, half the mice were killed and the tumour nodes were observed. The typical nodes were shown by the arrow. Scale bar, 1 cm. (a). The remaining mice were used for the long-term survival observation (b). Data are representative of three independent experiments. P<0.001, Cisplatin.MP group compared with PBS control group.
